EnzyTag

Executive Summary

EnzyTag is a Dutch biotechnology company leveraging its patented peptiligase technology to enable efficient and sustainable synthesis of peptides, small proteins, and complex bioconjugates such as ADCs, PROTACs, and LYTACs. Founded in 2010 and spun out in 2018, the company holds an exclusive worldwide license to this platform, which addresses key challenges in peptide synthesis, including traceless ligation and cyclization. By providing a green and cost-effective alternative to traditional methods, EnzyTag aims to accelerate the development of novel chemical entities for therapeutic applications. The company's technology has broad applicability across the biopharma landscape, particularly in the growing fields of targeted protein degradation and antibody-drug conjugates. With the global peptide therapeutics market projected to surpass $50 billion by 2027, EnzyTag is well-positioned to capture value through partnerships and licensing deals. While still early-stage, the platform's versatility and strong intellectual property offer a compelling investment opportunity. Key near-term catalysts include securing strategic collaborations and advancing proof-of-concept studies.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a biopharma for ADC development40% success
• Q4 2026Publication of proof-of-concept for PROTAC synthesis using peptiligase50% success
• Q4 2026Series A financing round to scale operations60% success